Dae Hwa 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases  2 Products   3 Trials   30 News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Liporaxel (paclitaxel oral) / Dae Hwa, HaiHe Biopharma
CTR20190050: A Phase III Clinical Study of Paclitaxel Oral Solution (RMX3001/DHP107) in the Treatment of Advanced Gastric Cancer

Ongoing
3
400
China
Liporaxel (paclitaxel oral) - Dae Hwa, HaiHe Biopharma
Daehua Pharmaceutical Co., Ltd./ Nomax (Shanghai) Pharmaceutical Technology Co., Ltd
Advanced gastric cancer
 
 
2020-000954-86: A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patients with Recurrent or metastatic HER2 negative Breast Cancer

Not yet recruiting
3
556
Europe, RoW
Liporaxel, Taxol, DHP107, Oral solution, Concentrate for solution for infusion, Liporaxel, Taxol
Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd.
Recurrent or metastatic HER2 negative Breast Cancer, Breast cancer patients with recurrent or metastatic HER2 gene negative, Diseases [C] - Cancer [C04]
 
 
OPTIMAL, NCT03315364 / 2020-000954-86: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Active, not recruiting
2/3
549
Europe, RoW
Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol®
Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd.
Recurrent or Metastatic Breast Cancer
02/24
12/25
2020-000960-52: A Multi-national, Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®, Oral Paclitaxel) Compared to IV Paclitaxel in Patients with Recurrent or Metastatic Breast Cancer

Not yet recruiting
2
72
RoW
Liporaxel, PACLITAXEL 100MG INJECTION 16.7ML, DHP107, Oral solution, Concentrate for solution for infusion, Liporaxel, PACLITAXEL 100MG INJECTION 16.7ML
Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd.
Recurrent or metastatic HER2 negative Breast Cancer, Breast cancer patients with recurrent or metastatic HER2 gene negative, Diseases [C] - Cancer [C04]
 
 
NCT06326346: GIST Oral Paclitaxel(Liporaxel)

Not yet recruiting
2
28
RoW
Liporaxel
Asan Medical Center
Gastrointestinal Stromal Tumors
03/27
03/27
FEEL, NCT04675528: Food Effect on Pharmacokinetics and Safety of DHP107 (Liporaxel®) Study

Completed
1
25
Europe
DHP107(Oral paclitaxel), Liporaxel®
Daehwa Pharmaceutical Co., Ltd.
Advanced Solid Tumor
12/22
12/22
DHP1401 / Dae Hwa
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Liporaxel (paclitaxel oral) / Dae Hwa, HaiHe Biopharma
CTR20190050: A Phase III Clinical Study of Paclitaxel Oral Solution (RMX3001/DHP107) in the Treatment of Advanced Gastric Cancer

Ongoing
3
400
China
Liporaxel (paclitaxel oral) - Dae Hwa, HaiHe Biopharma
Daehua Pharmaceutical Co., Ltd./ Nomax (Shanghai) Pharmaceutical Technology Co., Ltd
Advanced gastric cancer
 
 
2020-000954-86: A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patients with Recurrent or metastatic HER2 negative Breast Cancer

Not yet recruiting
3
556
Europe, RoW
Liporaxel, Taxol, DHP107, Oral solution, Concentrate for solution for infusion, Liporaxel, Taxol
Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd.
Recurrent or metastatic HER2 negative Breast Cancer, Breast cancer patients with recurrent or metastatic HER2 gene negative, Diseases [C] - Cancer [C04]
 
 
OPTIMAL, NCT03315364 / 2020-000954-86: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Active, not recruiting
2/3
549
Europe, RoW
Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol®
Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd.
Recurrent or Metastatic Breast Cancer
02/24
12/25
2020-000960-52: A Multi-national, Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®, Oral Paclitaxel) Compared to IV Paclitaxel in Patients with Recurrent or Metastatic Breast Cancer

Not yet recruiting
2
72
RoW
Liporaxel, PACLITAXEL 100MG INJECTION 16.7ML, DHP107, Oral solution, Concentrate for solution for infusion, Liporaxel, PACLITAXEL 100MG INJECTION 16.7ML
Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd.
Recurrent or metastatic HER2 negative Breast Cancer, Breast cancer patients with recurrent or metastatic HER2 gene negative, Diseases [C] - Cancer [C04]
 
 
NCT06326346: GIST Oral Paclitaxel(Liporaxel)

Not yet recruiting
2
28
RoW
Liporaxel
Asan Medical Center
Gastrointestinal Stromal Tumors
03/27
03/27
FEEL, NCT04675528: Food Effect on Pharmacokinetics and Safety of DHP107 (Liporaxel®) Study

Completed
1
25
Europe
DHP107(Oral paclitaxel), Liporaxel®
Daehwa Pharmaceutical Co., Ltd.
Advanced Solid Tumor
12/22
12/22
DHP1401 / Dae Hwa
No trials found

Download Options